Colorectal cancer (CRC), the second leading cause of cancer-related deaths in the US, has been treated with targeted therapies. However, the mechanisms of differential responses and resistance of CRCs to targeted therapies are not well understood. In this study, we found that genetic alterations of FBW7, an E3 ubiquitin ligase and a tumor suppressor frequently mutated in CRCs, contribute to resistance to targeted therapies. CRC cells containing FBW7-inactivating mutations are insensitive to clinically used multi-kinase inhibitors of RAS/RAF/MEK/ERK signaling, including regorafenib and sorafenib. In contrast, sensitivity to these agents is not affected by oncogenic mutations in KRAS, BRAF, PIK3CA or p53. These cells are defective in apoptosis owing to blocked degradation of Mcl-1, a pro-survival Bcl-2 family protein. Deleting FBW7 in FBW7-wild-type CRC cells abolishes Mcl-1 degradation and recapitulates the in vitro and in vivo drug-resistance phenotypes of FBW7-mutant cells. CRC cells selected for regorafenib resistance have progressive enrichment of pre-existing FBW7 hotspot mutations, and are cross-resistant to other targeted drugs that induce Mcl-1 degradation. Furthermore, a selective Mcl-1 inhibitor restores regorafenib sensitivity in CRC cells with intrinsic or acquired resistance. Together, our results demonstrate FBW7 mutational status as a key genetic determinant of CRC response to targeted therapies, and Mcl-1 as an attractive therapeutic target. -9232/17 www.nature.com/onc FBW7 mutations mediate resistance to targeted therapies J Tong et al FBW7 mutations mediate resistance to targeted therapies J Tong et al FBW7 mutations mediate resistance to targeted therapies J Tong et al FBW7 mutations mediate resistance to targeted therapies J Tong et al Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc) FBW7 mutations mediate resistance to targeted therapies J Tong et al
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancerrelated deaths in the US. 1 CRC progression is driven by a series of well-defined genetic alterations, including mutations in APC, BRAF, KRAS, PIK3CA, p53 and F-box and WD repeat domain-containing 7 (FBW7). 2, 3 FBW7, also known as FBXW7 and CDC4, is a tumor suppressor frequently mutated in human cancers, including~15-20% of CRCs. 4, 5 It functions as an E3 ubiquitin ligase, which binds to phosphorylated substrates to promote their ubiquitination and subsequent proteasomal degradation. 4 Heterozygous FBW7 missense mutations are often detected in three arginine residues (R465, R479 and R505) that bind to a conserved CDC4 phosphodegron motif of substrates upon phosphorylation. 4 Recent incorporation of targeted therapies has improved efficacy of CRC treatment. 6 Regorafenib and sorafenib, multikinase inhibitors for targeting RAS/RAF/MEK/ERK signaling, have been shown to increase overall patient survival and approved for treating solid tumors including CRCs. [7] [8] [9] [10] Regorafenib and sorafenib inhibit CRAF, BRAF, VEGFRs, PDGFR, c-Kit and other oncogenic kinases. 11, 12 Their anticancer effects are associated with induction of apoptosis, inhibition of cell proliferation and suppression of tumor angiogenesis. The success of targeted therapies is highly dependent on the identification of sensitive tumors, 13 exemplified by the use of KRAS mutational status to guide anti-EGFR therapies. 14 However, no genetic or epigenetic factors underlying differential responses and resistance to regorafenib or sorafenib have been identified, despite the need for molecular markers to predict responses to these drugs. 15 Killing of tumor cells by apoptosis is a key molecular mechanism of targeted therapies. 16 Stress-induced apoptosis in mammalian cells is mediated through mitochondria by the Bcl-2 family proteins, which collectively regulate apoptosis by triggering a cascade of events, including permeabilization of outer mitochondrial membrane, release of the mitochondrial proteins such as cytochrome c and activation of caspases. 17 Myeloid cell leukemia 1 (Mcl-1) is a pro-survival Bcl-2 family member frequently overexpressed in various tumors. 18 Distinctive from other Bcl-2 members, it is a very unstable protein. 19 Degradation of Mcl-1 can be triggered by various stresses, [20] [21] [22] [23] [24] and regulated by kinases such as glycogen synthase kinase 3β (GSK3β). 25 Recent studies identified FBW7 as an E3 ubiquitin ligase that targets phosphorylated Mcl-1 for destruction, 22, 26 suggesting that FBW7 mutations may affect responses to targeted therapies through Mcl-1.
To understand the mechanisms of resistance to targeted therapies, we investigated the functional roles of FBW7 mutations and Mcl-1 degradation in determining responses to targeted therapies. Our results suggest that FBW7 mutations mediate intrinsic and acquired resistance of CRCs to targeted agents by blocking Mcl-1 degradation.
RESULTS

CRC cells containing FBW7 mutations are insensitive to targeted drugs
To identify the genetic determinants of CRC response to targeted therapies, we analyzed a panel of 16 CRC cell lines with different mutations in common tumor suppressors and oncogenes, including KRAS, BRAF, PIK3CA, p53 and FBW7 ( Supplementary  Table S1 ). Cells were treated with regorafenib at different concentrations followed by analysis of cell viability using MTS assay. A striking correlation was found between regorafenib sensitivity and FBW7 mutational status ( Figure 1a ). All 8 FBW7mutant CRC cell lines were substantially less sensitive to regorafenib compared with 8 FBW7-wild-type (WT) cell lines, as indicated by higher inhibitory concentration 50 (IC 50 ) (Figure 1b and Supplementary Table S1 ). In contrast, no correlation was found between regorafenib sensitivity and genotypes of KRAS, BRAF, PIK3CA and p53 (Figure 1c ). The FBW7-mutant cell lines were also significantly less sensitive to sorafenib ( Supplementary Fig. S1 ; Supplementary Table S1 ). Most (6/8) of the analyzed FBW7-mutant cell lines contain a heterozygous missense mutation in the substrate-binding arginine or other residues of FBW7, except for SW837 and SW48, which harbor homozygous frame-shift insertion and heterozygous frame-shift deletion, respectively ( Table 1 and Supplementary Fig. S1C ). FBW7-mutant cell lines generally express lower levels of FBW7 protein than the WT cell lines ( Figure 1d ).
CRC cells containing FBW7 mutations lack Mcl-1 degradation
We then investigated the basis of regorafenib and sorafenib sensitivity in CRC cells. Regorafenib suppressed the viability of sensitive cell lines, including HCT116, Lim1215 and RKO cells, at doses that induced caspase activation characteristic of apoptosis induction ( Supplementary Fig. S2A ). Regorafenib induced substantially higher levels of apoptosis determined by nuclear fragmentation in FBW7-WT cell lines than in FBW7-mutant cell lines (Figure 2a ), suggesting FBW7 determines regorafenib sensitivity by regulating apoptosis. Analysis of Bcl-2 family members revealed dose-and time-dependent depletion of antiapoptotic Mcl-1 in regorafenib-treated HCT116 cells (Figure 2b , Supplementary Figures S2B and S7A ), which could be reverted by wash-out of regorafenib (Supplementary Figure S2C ). Mcl-1 depletion occurred prior to morphological changes of cell death, and required similar doses of regorafenib as those for caspase activation (Figure 2b and Supplementary Figure S2A ), suggesting a critical role in apoptosis initiation. An inverse correlation between FBW7 and Mcl-1 expression was found in untreated CRC cell lines, with FBW7-mutant cell lines generally expressing higher levels of Mcl-1 than WT cell lines (Figure 1d and Supplementary Figure S2D ). Upon regorafenib treatment, marked Mcl-1 depletion was detected in all eight WT cell lines, but not detected or much weaker in 8 FBW7-mutant cell lines ( Figure 2c ). Similarly, sorafenib also strongly induced Mcl-1 depletion only in WT cell lines ( Figure 2d ). In contrast, the expression of c-Myc and cyclin E, which are also FBW7 substrates, 4 were not significantly changed in regorafenib-treated HCT116 cells ( Supplementary Fig. S2E ). The striking correlation of regorafenib and sorafenib sensitivity with 
FBW7-dependent regorafenib and sorafenib sensitivity is mediated by Mcl-1 depletion
To determine the role of FBW7 in mediating regorafenib and sorafenib sensitivity, we analyzed isogenic FBW7-knockout (KO) HCT116 and DLD1 cells. 5 Compared with the WT cells, FBW7-KO cells were substantially more resistant to regorafenib ( WT FBW7, tumor-derived FBW7 mutants, including R465C, R479Q and R505C, failed to restore regorafenib sensitivity and Mcl-1 depletion in FBW7-KO cells (Figure 3c and Supplementary Figure S3E ). FBW7 transfection also restored regorafenib sensitivity and apoptosis induction in FBW7-mutant SW837 and SW48 cells (Figure 3d ; Supplementary Figure S3F and G). Treating FBW7-KO and FBW7-mutant cells with sorafenib yielded similar results (Supplementary Figure S4A -D). In contrast to FBW7-KO and FBW7mutant cells, isogenic CRC cell lines with an engineered change in KRAS, BRAF, PIK3CA or p53 status did not show any alteration in regorafenib sensitivity compared with the parental cells (Supplementary Figure S5A-D) , consistent with lack of correlation with the genotypes of these genes in the cell line panel (Figure 1c ). These results demonstrate that regorafenib and sorafenib sensitivity of CRC cells is dependent on FBW7, whose inactivating mutations cause intrinsic resistance to these drugs, likely through their effect on Mcl-1 depletion.
CRC cells with acquired regorafenib resistance have FBW7 hotspot mutations The above observations prompted us to test whether alterations in FBW7 are involved in acquired resistance to regorafenib. We generated regorafenib-resistant cell lines using regorafenibsensitive and FBW7-WT cell lines, including HCT116, DLD1, SW480, RKO, Lim1215 and Lim2405, by treating cells with four consecutive rounds of regorafenib. The survival cells (-R cells) were found to be highly resistant to regorafenib, showing increased cell viability ( Figures 4a and b and Supplementary Figure S6A ), and higher IC 50 compared with the parental cells ( Table 2 ). The regorafenib-resistant cell lines were found to have reduced apoptosis compared with their parental cell lines (Supplementary Figure S6B) . Remarkably, FBW7 mutations were identified in four out of six resistant cell lines, including R505C (c.1513C4T) in HCT116-R cells, R465C (c.1393C4T) in Lim1215-R and Lim2405-R cells and R479Q (c.1436G4A) in SW480-R cells ( Figure 4c and Table 2 ). These mutations account for 25-43% of FBW7 alleles in the resistant cells, determined by sequencing of individual clones of PCR products from genomic DNA ( Supplementary Fig. S6C ). They are the same hotspot mutations found in FBW7-mutant CRC cell lines and tumors (Table 1) . 5 Using allele-specific PCR assays that can detect rare FBW7 mutations in FBW7-WT cells, we found that the R505C mutation pre-existed in~0.03-0.1% of HCT116 cells, but became enriched upon each successive round of regorafenib treatment (Figure 4d ). Similarly, the R465C mutation also preexisted in Lim1215 and Lim2405 cells and was selected by regorafenib treatment (Figure 4d ). Consistent with the mutations, FBW7 mRNA expression, which was elevated in the parental cells upon regorafenib treatment, could not be induced by regorafenib in the resistant cell lines (Supplementary Figure S6D ).
Mcl-1 knockdown or inhibition restores regorafenib sensitivity in CRC cells
Upon regorafenib treatment, all of the resistant cell lines showed delayed and/or attenuated Mcl-1 degradation than the parental cell lines ( Figure 5a and Table 2 ), whereas other regorafenibinduced changes, including inhibition of ERK phosphorylation, dephosphorylation of GSK3β, and induction of PUMA and other Bcl-2 family proteins, 27 were intact in the resistant cell lines (Figure 5a and Supplementary Figure S7A ), suggesting acquired regorafenib resistance is mediated by blocked Mcl-1 degradation. Indeed, knockdown of Mcl-1 restored regorafenib sensitivity in each of the six resistant lines (Figure 5b and Supplementary Figure S7B) .
Several small-molecule inhibitors of the anti-apoptotic Bcl-2 family members have been identified, among which TW-37 was shown to be the most effective Mcl-1 inhibitor. 28 Treating cells with TW-37, but not ABT-737, a Bcl-2/Bcl-X L inhibitor that does not inhibit Mcl-1, 29 restored regorafenib-induced apoptosis in regorafenib-resistant and FBW7-KO HCT116 cells (Figure 5c and Supplementary Figure S7C ), suggesting that inhibiting Mcl-1 can overcome regorafenib resistance in CRC cells.
Regorafenib-resistant CRC cells are cross-resistant to other agents that induce Mcl-1 degradation
To determine whether the FBW7/Mcl-1 axis has a broad functional role in drug resistance, we analyzed the response of regorafenibresistant cells to other anticancer agents including targeted agents (Figure 5d ). Analysis of over 50 anticancer agents identified several additional targeted agents that can induce Mcl-1 degradation, including the multi-kinase inhibitors UCN-01 and Sunitinib, the CDK inhibitor Roscovitine and the survivin inhibitor YM-155 ( Figure 5e ). In response to each of these agents, apoptosis and Mcl-1 degradation were found to be suppressed in regorafenib-resistant HCT116, SW480 and Lim2405 cells compared with the parental cells (Figures 5d and e, Supplementary  Figures S8B and C) . In contrast, no change was detected in the sensitivity of regorafenib-resistant cells to the agents that did not induce Mcl-1 degradation, including the Met/Alk inhibitor crizotinib, the death receptor ligand TRAIL, the aurora kinase inhibitor VX680, the DNA-damaging agent etoposide, the mTORinhibitor temsirolimous and the non-steroidal anti-inflammatory drug sulindac sulfide (Figure 5d , Supplementary Figures S8B and  C) . These results suggest that deficiency in Mcl-1 degradation, frequently caused by FBW7-inactivating mutations, is widely involved in intrinsic and acquired resistance to different classes of anticancer agents in CRC cells.
FBW7 and Mcl-1 depletion mediate the in vivo antitumor effects of regorafenib
To determine the role of FBW7 in mediating the in vivo effects of regorafenib, WT and FBW7-KO HCT116 cells were injected subcutaneously into nude mice to establish xenograft tumors. Mice were then treated with 30 mg kg − 1 regorafenib or the control vehicle by oral gavage for 10 consecutive days. In contrast to WT tumors, FBW7-KO HCT116 tumors were substantially less sensitive to regorafenib treatment (Figures 6a and b) . Blocked Mcl-1 depletion but intact GSK3β de-phosphorylation was found in FBW7-KO tumors (Figure 6c ). Apoptosis analyzed by TUNEL and active caspase-3 staining was significantly reduced in the FBW7-KO tumors compared with WT tumors (Figures 6d and e ). Analysis of tumor vasculature by CD31 staining showed that the antiangiogenic effect of regorafenib was reduced in the FBW7-KO tumors (Figure 6f ). Suppression of tumor hypoxia, analyzed by Carbonic Anhydrase 9 (CA9) staining, by regorafenib was also decreased in the FBW7-KO tumors compared with WT tumors (Figure 6g ). These findings demonstrate a pivotal role of FBW7 and Mcl-1 degradation in mediating the antitumor effects of regorafenib.
DISCUSSION
Metastatic CRC is one of the most deadly cancers, characterized by poor prognosis and low-survival rate. Incorporation of targeted agents, including the anti-VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab, has improved efficacy of CRC treatment. 6 However, anticancer therapies, especially targeted therapies, often generate highly heterogeneous patient responses. A major goal of precision medicine is to prevent unnecessary treatments and therapy-associated adverse effects through patient stratification. For example, KRAS status has been used to guide anti-EGFR therapy on a CRC patient. 14 Our findings elucidate a critical functional role of FBW7 and Mcl-1 in differential sensitivity and resistance of CRC cells to targeted therapies.
Most of the FBW7 mutations in CRCs are heterozygous point mutations. It has been controversial as to how heterozygous FBW7 mutations abolish the protein function in cancer cells. Mutant FBW7 may have altered protein stability, 30 or act as dominant negative proteins upon hetero-dimerization with WT FBW7. 4 The lower levels of FBW7 in FBW7-mutant CRC cells ( Figure 1d ) suggest a gene dosage effect and altered protein stability. FBW7 mutations are found in various human cancers and likely have a broad functional role in determining therapeutic responses of cancer cells. 4 They have been shown to affect responses to γ-secretase inhibitors in leukemia cells, 31, 32 to HDAC inhibitors in squamous tumor cells, 33 and to antimitotic drugs in CRC cells. 22 FBW7 is an F-box protein that functions as a substrate receptor for SKP1-CUL1-F-box-type of ubiquitin ligase complexes to promote polyubiquitination. 34 In addition to Mcl-1, dozens of other FBW7 substrates have been identified, including Jun, Myc, cyclin E and Notch, which contain CDC4 phosphodegron motifs of various binding affinities for FBW7. 4 These substrates can be differentially affected by FBW7 mutations, underlying the agent-and cell-typedependent effects on therapeutic response.
FBW7 determines regorafenib and sorafenib sensitivity through proteasomal degradation of Mcl-1. It has been shown that upon GSK3β-dependent phosphorylation, phosphorylated Mcl-1 binds to FBW7 and recruited to the SCF ubiquitin ligase complex formed, 22 which can covalently link ubiquitin chains to Mcl-1, leading to its degradation in the 26S proteasome. 35 Several other kinases have also been implicated in regulating Mcl-1 turnover, including p38, JNK, CDK1 and casein kinase II. 22, 25, 26 FBW7 induction, which correlates with Mcl-1 degradation (Figure 3b ) and is likely responsible for FBW7 activation, may be related to transcriptional regulators of FBW7, such as microRNA 27a and C/EBPδ. 36, 37 Alternatively, the stability of FBW7 itself can be regulated by the deubiquitinase Usp28. 38 In addition to FBW7, Mcl-1 stability can be regulated by other E3 ubiquitin ligases such as Mule and β-TrCP, 24, 39 and by the deubiquitinase USP9X. 40 These proteins may also be involved in drug resistance mediated by Mcl-1 stabilization. Furthermore, a recent study showed that Mcl-1 stability is regulated by cyclin E/cdk2-dependent phosphorylation at specific sites, suggesting indirect regulation of Mcl-1 stability by FBW7 through cyclin E. 41 A major challenge in anticancer therapies is emergence of drug resistance. However, little is known about why initial therapeutic responses are short lived, with re-growing tumors insensitive to further treatment. 13 Acquired resistance to the anti-EGFR therapy has been associated with enrichment of KRAS-mutant CRC cells, 42, 43 suggesting a critical role of pre-existing or de novo oncogenic mutations in acquired resistance. Our data show that acquired regorafenib resistance can be due to enrichment of a small fraction of FBW7-mutant cells (Figure 4) . The nature of genomic instability that is responsible for generating these mutant cells remain to be identified. FBW7 genotype does not seem to be the sole determinant of regorafenib sensitivity, suggested by residual Mcl-1 degradation in some FBW7-mutant CRC cells ( Figure 2c ) and lack of FBW7 mutations in two out of six regorafenib-resistant cell lines ( Table 2 ). Other tumor suppressors or oncogenes that regulate the expression and protein stability of FBW7 and Mcl-1 may be involved in regorafenib and sorafenib resistance. The role of Mcl-1 in the intrinsic and acquired regorafenib resistance suggests that Mcl-1 inhibition is an effective approach for overcoming such resistance. The cell line and resistance models generated in this study can be useful for analysis of specific Mcl-1 targeting, which has been difficult to assess. 28 In parallel with ongoing clinical studies, our studies may establish FBW7 mutational status and Mcl-1 stability as key determinants of regorafenib and sorafenib sensitivity. They may provide a rationale for effective combinations of regorafenib and sorafenib with other drugs, for establishing the broad functional roles of FBW7 and Mcl-1 in targeted anticancer therapies, and for overcoming therapeutic resistance caused by genomic instability in cancer cells.
MATERIALS AND METHODS
Cell culture
The human CRC cell lines ( Supplementary Table S1 ), including HCT116, RKO, DLD1, LoVo, Lim1215, Lim2405, SW480, SNU-C2B, LS411N, SW48, SW1463, SW837 and HCT-8 were obtained from the American Type Culture Collection (Manassas, VA, USA). CCK-81, DiFi and NCI-H508 cells were obtained from Dr Alberto Bardelli at University of Torino in Italy. Isogenic p53-KO, FBW7-KO, KRAS-KO (WT or G13D mutant allele), PIK3CA-KO (WT or H1047R or E545K mutant allele) HCT116 or DLD1 cell lines, as well as BRAF-KO (WT or V600E mutant allele) RKO and VACO432 cells, were obtained either from Dr Bert Vogelstein at Johns Hopkins, or from Horizon Discovery (Cambridge, UK). The cell lines were last tested and authenticated for genotypes, drug-response, morphology and absence of mycoplasma in February 2016. Loss-of-expression of targeted proteins was confirmed by western blotting and Mycoplasma testing was performed routinely by PCR. Regorafenib-resistant cell lines were generated by exposing regorafenibsensitive HCT116, DLD1, RKO, SW480, Lim1215 and Lim2405 cells to 40 μM regorafenib for 3 days, followed by recovery for 5 days, and then repeated treatment/recovery for a total of 4 cycles.
All cell lines were maintained at 37°C in 5% CO 2 and cultured in McCoy's 5A modified media (Invitrogen, Carlsbad, CA, USA) supplemented with 10% defined FBS (HyClone, Logan, UT, USA), 100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). For drug treatment, cells were plated in 12-well plates at 20 to 30% density 24 h before treatment. The DMSO (Sigma, St Louis, MO, USA) stocks of agents used, including regorafenib, sorafenib, TW-37, ABT-737, UCN-01, YM-155, roscovitine, sunitinib, crizotinib, VX680, etoposide, temsirolimus, and sulindac (Selleck Chemicals, Houston, TX, USA), were diluted to appropriate concentrations with the cell culture medium. TRAIL (XcessBio, San Diego, CA, USA) was diluted with distilled water.
MTS assay
CRC cells were seeded in 96-well plates at a density of 1 × 10 4 cells per well. After overnight incubation, cells were treated with regorafenib for 72 h. MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay was performed using the MTS assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Luminescence was measured with a Wallac Victor 1420 Multilabel Counter (PerkinElmer, Waltham, MA, USA). Each assay was conducted in triplicate and repeated three times.
Western blotting
Western blotting was performed as previously described, 44 with antibodies for PUMA, 45 Akt, phospho-Akt (S473), ERK, phospho-ERK (T202/Y204), GSK3β, phospho-GSK3β (S9) (Cell Signaling, Danvers, MA, USA), Bak (Millipore, Bellerica, MA, USA), Bax, cyclin E, c-Myc, Mcl-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-2 (Dako, Carpinteria, CA, USA), Bim, Bid, Noxa, and β-actin (EMD Biosciences, Philadelphia, PA, USA), HA and Bcl-X L (BD Biosciences, San Jose, CA, USA). 
Transfection and siRNA knockdown
Genomic and reverse-transcriptase PCR
To detect FBW7 hotspot mutations in parental and regorafenib-resistant cells, genomic DNA was isolated from 5-10 × 10 4 cells by using ZR-96 Quick-gDNA Kit (ZYMO Research, Irvine, CA, USA) according to the manufacturer's instructions. In all, 1 μl out of 50 μl genomic DNA preparation was used for PCR using previously described conditions 46 and primers listed in Supplementary Table S2 . Cycle conditions are available upon request. For analysis of FBW7 mRNA expression, total RNA was isolated from cells using the Mini RNA Isolation II kit (ZYMO Research) according to the manufacturer's protocol. In all, 1 μg of total RNA was used to generate cDNA using SuperScript II reverse transcriptase (Invitrogen). Real-time PCR was carried out using the primer pairs listed in Supplementary Table S2 as described. 46 
Analysis of apoptosis
Adherent and floating cells were harvested, stained with Hoechst 33258 (Invitrogen), and analyzed for apoptosis by nuclear staining assay. A minimum of 300 cells were analyzed for each treatment. Caspase activity was measured using the SensoLyte Homogeneous AMC Caspase-3/7 Assay Kit (Anaspec, Fremont, CA, USA) as previously described. 47 
Xenograft tumor experiments
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Female 5-to 6-week-old Nu/Nu mice (Charles River, Wilmington, MA, USA) were housed in a sterile environment with micro isolator cages and allowed access to water and chow ad libitum. Mice were injected subcutaneously with 4 × 10 6 WT or FBW7-KO HCT116 cells. After tumor growth for 7 days, mice were treated daily with regorafenib at 30 mg kg − 1 by oral gavage for 10 consecutive days. Regorafenib was dissolved in Cremephor EL/95% ethanol (50:50) as a 4 × stock solution. Tumor growth was monitored by calipers, and tumor volumes were calculated according to the formula 0.5 × length × width 2 . Mice were killed when tumors reached 1.0 cm 3 in size. Tumors were dissected and fixed in 10% formalin and embedded in paraffin. Terminal deoxynucleotidyl transferase mediated dUTP Nick End Labeling (TUNEL; Millipore), active caspase-3 (Cell Signaling), CD31 (Spring Bioscience, Pleasanton, CA, USA) and Carbonic Anhydrase 9 (CA9; Santa Cruz Biotechnology) immunostaining was performed on 5 μm paraffinembedded tumor sections as previously described, 48 by using an AlexaFluor 488-conjugated secondary antibody (Invitrogen) for detection.
Statistical Analysis
Statistical analyses were carried out using GraphPad Prism IV software (GraphPad Software, Inc., La Jolla, CA, USA). P-values were calculated by the Student's t-test and were considered significant if Po0.05. The means ± one standard deviation were displayed in the figures.
